3,4-CTMP (3,4-dichloromethylphenidate; also written 3,4-DCMP) is a synthetic stimulant in the substituted phenidate class, a structural derivative of methylphenidate (Ritalin) with dichlorine substitution at the 3 and 4 positions of the phenyl ring. It is among the most potent and dangerous novel stimulants to appear in the research chemical market, characterized by a combination of extreme potency-to-dose ratio, unusually long duration (6–12 hours), high addiction potential, and narrow therapeutic-to-toxic margin.
3,4-CTMP emerged in UK and European markets around 2013–2015. Reports of hospitalizations and suspected fatalities, along with a pattern of compulsive use and difficulty stopping, led to rapid emergency scheduling in multiple jurisdictions. The compound exemplifies a class of research chemicals where the initial pharmacological novelty attracted users, but the unfamiliar risk profile — particularly the dramatically higher potency than expected from the dose — led to severe adverse events before the community had developed adequate harm-reduction knowledge. The serotonergic activity of 3,4-CTMP, which is unusual among phenidates, adds to its complexity and risk.
Safety at a Glance
High Risk- Critical Warning: Disproportionate Potency
- Threshold: 1–3 mg | Common: 3–8 mg | Strong: 8–14 mg
- Toxicity: Documented Harm 3,4-CTMP has been associated with hospitalizations and suspected deaths — a documented harm profile t...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: fatal heart disease when used for even relatively short periods of time. It is highly recommended...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 6 hrs – 18 hrsHow It Feels
The onset of 3,4-CTMP is measured and deliberate. Forty-five minutes to an hour after oral ingestion, a steady current of wakefulness begins to build. The mind clears incrementally, attention becomes more adhesive, and there is a gradual awareness that the usual mental friction, the small resistances that make starting tasks effortful, has been quietly reduced. The body registers a mild increase in heart rate and a subtle tension in the muscles, but these are gentle accompaniments to a primarily cognitive shift.
As the effects develop over the following hour, 3,4-CTMP settles into a sustained, functional plateau. Focus deepens into something reliable and consistent. Tasks that require sustained attention become more approachable, and the mind stays on track without the constant redirection that characterizes normal cognitive wandering. The stimulation is clean but somewhat colorless, there is alertness and capability but little warmth or pleasure. Mood is neutral to mildly positive. Conversations are lucid but lack the animated quality that more euphoric stimulants bring. The body feels awake and slightly tense, with reduced appetite and a mild dryness in the mouth.
At the peak, roughly two to three hours in, the defining characteristic of 3,4-CTMP is its longevity rather than its intensity. The stimulation is moderate but it persists with a stubbornness that exceeds most compounds in its class. Hours pass with a uniform quality of alert productivity. There is no euphoric crest followed by a valley, just a long, flat mesa of enhanced function. The physical side effects, elevated heart rate, vasoconstriction, appetite suppression, maintain the same steady intensity throughout, which can become wearing over the extended duration.
The offset is where the compound's character becomes most apparent. The active effects can persist for ten to fourteen hours, and the taper is exceptionally slow. Long after you would like the stimulation to end, a residual wakefulness clings on, making sleep elusive. There is no dramatic crash, but the sheer duration can leave the user feeling worn and depleted by the time baseline finally returns. Restlessness, irritability, and difficulty sleeping may extend well into the night or even the following day. The lesson of 3,4-CTMP is one of patience: it arrives without drama and leaves on its own protracted schedule.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(19)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Brain zaps— Brain zaps are sudden, brief, electrical shock-like sensations that originate in the head and someti...
- Decreased blood pressure— Decreased blood pressure (hypotension) is a drop in arterial blood pressure below normal levels, com...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temporary erectile dysfunction— Temporary erectile dysfunction is the substance-induced inability to achieve or sustain a penile ere...
- Tinnitus— Phantom perception of ringing, buzzing, or hissing in the ears without external sound source, potent...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(4)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
Cognitive(20)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive dysphoria— A cognitive and emotional state of intense dissatisfaction, discomfort, and malaise encompassing fee...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Ego inflation— Grandiose overconfidence and inflated self-importance, opposite of ego death, commonly produced by s...
- Emotion suppression— A blunting or flattening of emotional experience in which feelings become muted, distant, or seeming...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought organization— Enhanced ability to structure, categorize, and systematize thoughts and ideas, common with low-dose ...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
3,4-CTMP is a potent monoamine reuptake inhibitor acting primarily at the dopamine transporter (DAT) and norepinephrine transporter (NET), consistent with the phenidate class mechanism. The 3,4-dichlorination of the phenyl ring produces a compound with substantially increased lipophilicity and altered transporter binding kinetics compared to methylphenidate.
The dichlorination is associated with a higher selectivity for the serotonin transporter (SERT) than other phenidates — a pharmacologically rare characteristic for this class. This serotonergic activity may contribute to the more pronounced euphoria and unusual subjective character reported relative to methylphenidate, and raises the risk profile for serotonin-related adverse effects.
Potency Context
3,4-CTMP is estimated to be significantly more potent than methylphenidate by weight — estimates suggest 5–10x or greater potency at DAT. The practical consequence is that milligram-for-milligram comparisons to familiar reference compounds dramatically underestimate its activity. Doses that appear small based on phenidate class experience are pharmacologically substantial.
Pharmacokinetics
3,4-CTMP has an unusually long duration for a phenidate — 6–12 hours at typical doses, substantially longer than methylphenidate (3–5 hours). The extended duration reflects altered metabolic pathways due to the halogenated ring, reducing first-pass clearance. The prolonged dopaminergic and noradrenergic stimulation increases both cardiovascular burden and addiction liability relative to shorter-acting stimulants.
Detection Methods
Standard Drug Panel Inclusion
3,4-CTMP (3,4-Dichloromethylphenidate) is a phenidate-class stimulant that is not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. Phenidates are structurally distinct from amphetamines and do not cross-react with amphetamine or methamphetamine antibodies used in commercial immunoassays. There is no dedicated phenidate channel on any standard workplace or clinical drug panel.
Urine Detection
3,4-CTMP (3,4-Dichloromethylphenidate) and its primary metabolite ritalinic acid (or the corresponding deesterified acid analogue) can be detected in urine for approximately 1 to 3 days after a single oral dose. The ester bond in phenidate compounds is rapidly hydrolyzed by plasma and hepatic esterases, producing the corresponding acid metabolite which is the dominant species found in urine. Higher doses or repeated administration may extend the detection window modestly.
Blood and Saliva Detection
Blood concentrations of 3,4-CTMP (3,4-Dichloromethylphenidate) decline rapidly due to ester hydrolysis, with a detection window of approximately 6 to 24 hours for the parent compound. The acid metabolite persists longer in plasma, detectable for up to 48 hours. Oral fluid testing can detect the parent compound for approximately 12 to 36 hours, though this route of detection is rarely employed for phenidates in practice.
Hair Follicle Detection
Hair follicle analysis may detect 3,4-CTMP (3,4-Dichloromethylphenidate) or its metabolites for up to 90 days. However, incorporation of phenidate-class compounds into hair has not been extensively studied, and commercial laboratories do not routinely test for these substances. Specialized forensic laboratories with LC-MS/MS capability and appropriate reference standards would be required.
Confirmatory Testing
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for confirming the presence of 3,4-CTMP (3,4-Dichloromethylphenidate) and its metabolites. The ester bond in phenidates makes them somewhat labile under GC-MS conditions, so LC-MS/MS is preferred. Both parent compound and the deesterified acid metabolite should be targeted for comprehensive analysis.
Reagent Testing
Marquis reagent typically shows no reaction or a very faint color change with 3,4-CTMP (3,4-Dichloromethylphenidate), which helps distinguish it from amphetamines (orange-brown) and MDMA (purple-black). Mecke reagent generally shows no reaction. Mandelin reagent may produce a faint yellow or no change. The absence of strong reagent reactions is characteristic of the phenidate class and is itself a useful piece of information when combined with other reagent results.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Emergence and Rapid Scheduling
3,4-CTMP appeared in UK research chemical markets circa 2013–2015, positioned as a novel phenidate stimulant. Reports of serious adverse events — including hospitalizations and suspected fatalities — prompted emergency scheduling. The UK Psychoactive Substances Act 2016 and the prior analogue legislation effectively prohibited it, and most European jurisdictions followed.
Significance as a Harm Case
3,4-CTMP is frequently cited in harm-reduction and pharmacology literature as an example of research chemical dangers: a compound that appeared related to a well-characterized drug (methylphenidate) but whose modified structure produced a qualitatively different and substantially more dangerous risk profile. The disproportionate potency and unusual serotonergic activity were not anticipated based on the parent compound.
Legal Status
Scheduled in the UK, Germany, Sweden, and most European jurisdictions. In the United States it is subject to Federal Analogue Act provisions as a methylphenidate analogue. International control has limited but not eliminated its availability through research chemical supply chains.
Harm Reduction
Critical Warning: Disproportionate Potency
The single most important harm-reduction message for 3,4-CTMP: this compound is dramatically more potent by weight than methylphenidate or most other phenidate stimulants. Dosing based on experience with methylphenidate or amphetamines will lead to overdose.
Dose Guidelines
- Threshold: 1–3 mg |Common: 3–8 mg |Strong: 8–14 mg
- Doses should be weighed on a milligram-capable scale — volumetric dosing or "eyeballing" is unacceptably hazardous at this potency level
- First experiences should begin at 2–3 mg maximum; the long duration means consequences persist for many hours
Duration Planning
Expect 6–12 hours of activity. Do not redose within the first 4–6 hours regardless of perceived inadequacy. The long duration and high re-stimulation potential make sequential redosing a direct path to toxicity and compulsive binge patterns.
Addiction Risk Management
Given the documented high addiction and compulsive-use liability, this substance is not appropriate for individuals with stimulant use disorder history or dopamine dysregulation disorders. If use is undertaken, strict interval rules (weeks rather than days between uses) and pre-planned hard stops (limited supply) are protective practices.
Seek Emergency Care
If experiencing chest pain, irregular heartbeat, difficulty breathing, extreme agitation, seizures, or any sign of cardiovascular crisis, seek emergency medical care immediately. Be forthright with medical providers about what was taken.
Toxicity & Safety
Documented Harm
3,4-CTMP has been associated with hospitalizations and suspected deaths — a documented harm profile that distinguishes it from most research chemical stimulants. Adverse events include cardiovascular complications, apparent overdose, and complications from compulsive redosing and prolonged use. The exact mechanism of the most severe reported cases is not always clear, but the combination of high potency, long duration, and serotonergic activity is implicated.
Cardiovascular Toxicity
Potent dopamine and norepinephrine reuptake inhibition produces significant cardiovascular stimulation — tachycardia, hypertension, vasoconstriction — sustained over 6–12 hours. The prolonged nature of this cardiovascular burden substantially increases risk compared to short-acting stimulants, particularly in the context of multiple redoses.
Addiction and Compulsive Use
The extended potent dopaminergic stimulation produces strong positive reinforcement, and the duration of action extends the "binge window." Reports of compulsive redosing, inability to stop, prolonged wakefulness, and severe withdrawal are common in user accounts. The addiction and dependence liability appears disproportionately high relative to other phenidate class stimulants.
Serotonin Syndrome Risk
The unusual SERT activity means 3,4-CTMP should not be combined with MAOIs, SSRIs, or other serotonergic drugs — a contraindication not typically associated with phenidate class stimulants.
Severe Contraindications
- MAOIs — serotonin syndrome risk
- Cardiovascular disease, hypertension, arrhythmias
- History of stimulant addiction or psychosis
- Any concurrent stimulant medication
Overdose Information
fatal heart disease when used for even relatively short periods of time. It is highly recommended that, should one choose to use this substance despite these concerns, it only be taken very sparingly and in low doses. Those with cardiovascular diseases of any kind should not consume this substance. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
Extreme caution must be taken when managing one's 3,4-CTMP usage as the duration of its stimulating effects can be very long, which can cause unwanted sleep inhibition. This should be considered when redosing as the physically stimulating effects of a dose may persist after the psychological effects have worn off. A user attempting to maintain a state of euphoria may run the risk of accumulating medically dangerous quantities of the substance in their bloodstream.
It is strongly recommended that one not insufflate 3,4-CTMP as it has a low solubility in water so is not readily absorbed through the nasal mucus membrane and anecdotal reports suggest that insufflation of the substance is painful and potentially extremely caustic. Additionally, the poor adsorption by the nasal mucus membrane often results in the majority of the substance slowly entering the stomach through a post-nasal drip, making the onset duration even longer, which may increase the chance of an 'accidental overdose' if one redoses more due to a lack of effect.
It is strongly recommended that one use harm reduction practices when choosing to use this substance.
In terms of its tolerance, many users have reported that 3,4-CTMP can be used for multiple days in a row for extended periods of time without any noticeable acute tolerance build up, instead increasing gradually over regular and extended use. Unusually, there are some reports indicating a sudden rise in tolerance after an extended period of relatively little increase. This results in the user
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | Develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Canada: 3,4-CTMP is a Schedule III controlled substance in Canada.
China: As of October 2015 3,4-CTMP is a controlled substance in China.
Germany: 3,4-Dichloromethylphenidate is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: 3,4-CTMP is a controlled substance in Japan effective March 6th, 2014.
Sweden: 3,4-Dichloromethylphenidate is illegal as of 10 November 2014.
Switzerland: 3,4-CTMP is a controlled substance specifically named under Verzeichnis E.
Turkey:** 3,4-Dichloromethylphenidate is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 3,4-Dichloromethylphenidate is a class B drug in the UK as of 31st May 2017 and is illegal to possess, produce or supply.
United States: 3,4-Dichloromethylphenidate is not explicitly controlled in the US, but it could possibly be considered an analog of a Schedule II substance (methylphenidate) under the Federal Analog Act.
Responsible use
Designer drug
Stimulant
Methylphenidate
3,4-CTMP (Wikipedia)
3,4-CTMP (Isomer Design)
3,4-CTMP (Drugs-Forum)
Experience Reports (1)
Tips (4)
Monitor your heart rate and blood pressure when using 3,4-CTMP. Sustained elevated cardiovascular stress causes cumulative damage. If you experience chest pain, irregular heartbeat, or numbness in extremities, seek medical attention.
Eat a substantial meal before taking 3,4-CTMP. Stimulants suppress appetite heavily, and going many hours without food leads to worse crashes, irritability, and cognitive impairment. Set phone reminders to eat and drink.
Weigh your dose of 3,4-CTMP with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
Have a landing plan for the 3,4-CTMP comedown. Prepare food, melatonin or magnesium, and a comfortable environment in advance. Avoid using depressants to manage the comedown as this creates polydrug dependency patterns.
See Also
References (3)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- 3,4-CTMP - TripSit Factsheet
TripSit factsheet for 3,4-CTMP
tripsit - 3,4-CTMP - Wikipedia
Wikipedia article on 3,4-CTMP
wikipedia